According to the World Health Organization (WHO), cardiovascular diseases (CVDs) represent a leading cause of mortality globally. In 2019, an estimated 17.9 million people died from CVDs, accounting for 32% of global mortality. 85% of those deaths are related to heart attacks and strokes 1.
In China, about 330 million people have CVDs, and CVDs are responsible for 2 out of every 5 deaths2. As one of the main causes of cardiovascular disease, hyperlipidemia has become a disease that cannot be ignored, and the number of dyslipidemia cases in China has exceeded 400 million3. In US, about 0.9 million people died from CVD in 20194. In Europe, there were an estimated 113 million people living with CVD5. Due to the dual pressures of an aging population and lifestyle, the incidence of CVDs will continue to rise.
CVDs affect a large portion of the population and require prolonged treatment due to their chronic nature. Therefore, CVDs will remain a major therapeutic area with enormous unmet global need.
Approved cardiovascular drugs have shortcomings including poor patient compliance, frequent dosing, and side effects which altogether can impact treatment outcomes. Cardiovascular patients could benefit from novel therapies that offer improved safety and durable efficacy.
RNAi medicine can impact chronic disease by expanding the range of drug targets with durable efficacy. First-generation RNAi therapeutics indicate potential for drastically improved patient-friendliness and compliance by extending dosing intervals to six months or perhaps longer. RNAi may also outperform other drug modalities such as oral small molecules or injectable proteins in compliance, dose regimen, safety, and efficacy.
Sirius is pioneering RNA innovation and broadening the therapeutic applications of RNAi to bring novel therapies to patients for improved quality of life.